Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $19.00

Travere Therapeutics (NASDAQ:TVTX) had its target price hoisted by HC Wainwright from $17.00 to $19.00 in a research note released on Wednesday morning, Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Travere Therapeutics’ FY2025 earnings at ($1.80) EPS, FY2026 earnings at $0.20 EPS, FY2027 earnings at $1.98 EPS and FY2028 earnings at $4.29 EPS.

Several other equities research analysts have also issued reports on TVTX. Wedbush reaffirmed an outperform rating and set a $13.00 target price on shares of Travere Therapeutics in a research report on Wednesday, April 17th. Piper Sandler raised their target price on Travere Therapeutics from $10.00 to $11.00 and gave the company a neutral rating in a research report on Thursday, January 18th. Guggenheim reaffirmed a neutral rating on shares of Travere Therapeutics in a research report on Wednesday, March 27th. Finally, Wells Fargo & Company lifted their price objective on Travere Therapeutics from $8.00 to $9.00 and gave the stock an equal weight rating in a report on Friday, February 16th. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and an average price target of $18.00.

Travere Therapeutics Price Performance

Shares of TVTX opened at $5.26 on Wednesday. Travere Therapeutics has a 12-month low of $5.12 and a 12-month high of $22.75. The business’s fifty day moving average is $7.28 and its 200 day moving average is $7.65. The company has a quick ratio of 3.41, a current ratio of 3.47 and a debt-to-equity ratio of 1.88. The stock has a market cap of $400.34 million, a P/E ratio of -3.27 and a beta of 0.58.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings data on Thursday, February 15th. The company reported ($1.16) earnings per share for the quarter, beating the consensus estimate of ($1.27) by $0.11. Travere Therapeutics had a negative return on equity of 177.97% and a negative net margin of 56.02%. The business had revenue of $45.06 million for the quarter, compared to analysts’ expectations of $41.25 million. Sell-side analysts anticipate that Travere Therapeutics will post -3.1 earnings per share for the current fiscal year.

Insider Buying and Selling at Travere Therapeutics

In other Travere Therapeutics news, SVP William E. Rote sold 4,764 shares of Travere Therapeutics stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $8.71, for a total transaction of $41,494.44. Following the completion of the transaction, the senior vice president now owns 80,720 shares of the company’s stock, valued at approximately $703,071.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, SVP William E. Rote sold 4,764 shares of Travere Therapeutics stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $8.71, for a total transaction of $41,494.44. Following the completion of the sale, the senior vice president now owns 80,720 shares in the company, valued at approximately $703,071.20. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Peter Heerma sold 4,195 shares of Travere Therapeutics stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $8.53, for a total value of $35,783.35. Following the sale, the insider now owns 99,503 shares of the company’s stock, valued at approximately $848,760.59. The disclosure for this sale can be found here. Insiders sold 34,773 shares of company stock valued at $300,625 in the last quarter. 3.75% of the stock is currently owned by corporate insiders.

Institutional Trading of Travere Therapeutics

A number of large investors have recently modified their holdings of TVTX. SG Americas Securities LLC bought a new stake in shares of Travere Therapeutics during the 3rd quarter valued at about $1,179,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Travere Therapeutics by 32.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,511 shares of the company’s stock worth $148,000 after buying an additional 4,007 shares during the last quarter. Emerald Advisers LLC lifted its position in Travere Therapeutics by 64.9% in the 3rd quarter. Emerald Advisers LLC now owns 1,060,302 shares of the company’s stock worth $9,479,000 after buying an additional 417,250 shares during the last quarter. Emerald Mutual Fund Advisers Trust lifted its position in Travere Therapeutics by 44.4% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 764,603 shares of the company’s stock worth $6,836,000 after buying an additional 235,085 shares during the last quarter. Finally, Cheyne Capital Management UK LLP bought a new stake in Travere Therapeutics in the 3rd quarter worth approximately $234,000.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.